Rhodiola Rosea: Human Evidence, Extracts, and Label Guide

Rhodiola rosea is a plant whose root and rhizome are used in herbal preparations. Supplements commonly position it for stress, fatigue, focus, mood, or exercise. The term adaptogen is also common, but that word does not identify the species, plant part, extraction method, dose, or evidence behind a product.

The European Medicines Agency recognizes a specific Rhodiola rosea dry extract for traditional use in the temporary relief of stress symptoms such as fatigue and exhaustion. This classification is based exclusively on long-standing use under defined conditions, not well-established clinical efficacy. ^{1 2}

A label that says only “Rhodiola” leaves the botanical identity incomplete. Human studies of a defined Rhodiola rosea extract cannot automatically be used to interpret Rhodiola crenulata, another Rhodiola species, or a generic multi-species blend.

Salidroside occurs in several Rhodiola species, so salidroside alone does not establish that the source is Rhodiola rosea. Rosavins are more useful for distinguishing R. rosea in analytical work, but a marker claim printed on a label still is not laboratory confirmation of the finished capsule. ¹¹

Rosavins usually refers to the combined marker group rosavin, rosarin, and rosin. Salidroside, also called rhodioloside, is a separate marker. These compounds help describe and compare extracts, but a percentage is not by itself proof of efficacy, botanical authenticity, or manufacturing quality.

A label showing 3% rosavins and 1% salidroside follows a familiar commercial pattern, but it is not a universal requirement. Health Canada’s 2025 monograph allows a wider standardized-extract range of 0.8% to 3% salidroside and/or 1% to 6% rosavins under its specified product conditions. ³

The most studied context is fatigue or mental performance during stressful conditions. Some small trials of named or standardized extracts reported changes in selected fatigue, attention, or mental-work measures. Other controlled research did not confirm a benefit.

A 2012 systematic review included 11 controlled studies and found contradictory results. Every included trial had either a high risk of bias or reporting limitations that prevented a confident assessment. The authors concluded that better designed, independently replicated trials were needed. ⁶

In a 60-person trial, 576 mg per day of the SHR-5 extract was studied for 28 days in people with stress-related fatigue. Both groups improved, while the Rhodiola group differed from placebo on selected measures. ⁷ In a later 42-day trial involving nursing students working shifts, the primary fatigue results favored placebo. ⁸

EFSA concluded that a cause-and-effect relationship had not been established between the evaluated Rhodiola extract and reduced mental fatigue. NCCIH likewise states that there is not enough reliable evidence to determine whether Rhodiola is useful for any health-related purpose. ^{4, 5}

A large extraction ratio is not a complete quality statement

Claims such as 10:1 or 200:1 may describe a relationship between botanical input and extract output. They do not reveal the species, extraction solvent, marker profile, actual marker amount, or whether the finished product matches a clinical preparation.

These examples compare disclosure quality and ingredient identity. They do not rank real products, verify bottle contents, or recommend a dose.

The best-disclosed label is not automatically the best product

Clear identity and marker information make the formula easier to interpret. They do not establish that the product contains the declared amount, reproduces a named extract, works for a symptom, or is suitable for a particular person.

The 2024 EMA traditional-use monograph describes a specific Rhodiola rosea root and rhizome dry extract with a drug-extract ratio of 1.5 to 5:1 and 67% to 70% ethanol as the extraction solvent. It lists 144 to 200 mg per dose, taken once or twice daily, for a total of 144 to 400 mg per day. ¹

Health Canada’s 2025 monograph allows 144 to 680 mg per day for standardized dry extracts under its defined marker and labeling conditions, with no more than 200 mg per single dose. ³ The 576 mg amount in the stress-related fatigue trial belonged to a named SHR-5 extract, a specific population, and 28 days of use. ⁷

EMA lists headache, nausea, abdominal pain, diarrhea, rash, and itching among reported adverse effects. Health Canada advises avoiding use before bedtime and stopping if irritability or insomnia occurs. ^{1, 3}

Most clinical studies are too small and short to establish complete long-term safety. Interaction data are also limited. One published case report described restlessness and trembling after Rhodiola was added to paroxetine, but a case report cannot define the risk for every antidepressant or product. ¹³